Innovation in cardiovascular disease in Europe with focus on arrhythmias: current status, opportunities, roadblocks, and the role of multiple stakeholders
Open Access
- 12 June 2017
- journal article
- research article
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 20 (5) , 733-738
Abstract
The European Heart Rhythm Association (EHRA) held an Innovation Forum in February 2016, to consider issues around innovation. The objective of the forum was to extend the innovation debate outside of the narrow world of arrhythmia specialists and cardiology in general, and seek input from all stakeholders including regulators, strategists, technologists, industry, academia, health providers, medical societies, payers, and patients. Innovation is indispensable for a continuing improvement in health care, preferably at higher efficacy and lower costs. It requires people who have been trained in a good scientific environment, high-quality research for achieving ground breaking inventions and the certainty of return on innovation investments. In the context of cardiovascular disease, innovation can imply better risk assessment and stratification, device technology, drug development, and process design. Several areas of promising developments were identified as well as several roadblocks to innovation. To drive innovation forward all stakeholders need to play a significant role. In a globalized and extremely competitive world, the leading role of Europe in medical innovation can only be achieved through a combined and well-coordinated effort from all involved parties.Keywords
This publication has 16 references indexed in Scilit:
- The application of Big Data in medicine: current implications and future directionsJournal of Interventional Cardiac Electrophysiology, 2016
- How scientists fool themselves – and how they can stopNature, 2015
- Barriers to cardiovascular device innovation in EuropeEuropean Heart Journal, 2015
- Statistics: P values are just the tip of the icebergNature, 2015
- Gene therapy to treat cardiac arrhythmiasNature Reviews Cardiology, 2015
- Editorial: The Innovative Medicines Initiative – collaborations are key to innovating R&D processesBiotechnology Journal, 2014
- Impact of Genetics on the Clinical Management of ChannelopathiesJACC, 2013
- A Tale of Coronary Artery Disease and Myocardial InfarctionNew England Journal of Medicine, 2012
- Believe it or not: how much can we rely on published data on potential drug targets?Nature Reviews Drug Discovery, 2011
- Drug development costs when financial risk is measured using the Fama–French three‐factor modelHealth Economics, 2010